MSD and Verily (formerly Google Life Sciences) are teaming up with NHS England to launch the Long Term Conditions Early Intervention Programme, aimed at evaluating the impact of new technologies in preventing costly long term conditions (LTCs).
The Programme will use a combination of traditional healthcare data, such as electronic health records, with non-traditional data (including environmental and socio-economic factors) to predict which patients are at risk of LTCs.
Those patients will then be supported to use telecare and remote devices in their homes so that doctors can help monitor signs and symptoms, and offer lifestyle advice and medication to help prevent the condition developing.
The Heywood, Middleton and Rochdale Clinical Commissioning Group (HMR CCG) has been chosen by NHS England as the first site for the two-year pilot scheme. If the scheme is successful it will be rolled out in other areas.
Chief executive of NHS England Simon Stevens said: “Over the next decade major health gains won’t just come from a few ‘miracle cures’, but also from combining diverse breakthroughs in fields such as biosensors, medtech and drug discovery, mobile communications, and AI computing.
“Our new programmes aim to cut through the hype and test the practical benefits for patients when we bring together some of these most promising technologies in receptive environments inside the world’s largest public, integrated health service.”
Mike Nally, managing director of MSD in the UK said: “We are delighted that we’ve been given this opportunity to help support innovation and the delivery of better patient outcomes in the NHS. The NHS is evolving and MSD, as a responsible partner, is doing everything it can to rise to these challenges and play its part in developing and delivering solutions to address some of the greatest future healthcare needs in the UK.”
